Abstract
In this article, the author reviews the historical aspects of the development of neuroprotective drugs including a oxygen radical scavenger, NXY-059 and discusses the missing steps in translating bone marrow stromal cell (BMSC) transplantation for cerebral stroke from laboratory to clinic. Furthermore, the authors describes what we should scientifically clarify to apply BMSC transplantation therapy into the patients with cerebral stroke.